| Trial ID: | L0148 |
| Source ID: | NCT00111995
|
| Associated Drug: |
Aranesp®
|
| Title: |
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Failure|Anemia
|
| Interventions: |
DRUG: Aranesp®
|
| Outcome Measures: |
Primary: Mean hemoglobin level during the evaluation period | Secondary: The nature, frequency, severity, relationship to treatment, and outcome of adverse events with specific attention to hypertensive events
|
| Sponsor/Collaborators: |
Sponsor: Amgen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
400
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: PREVENTION
|
| Start Date: |
2002-05
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2008-08-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00111995
|
